title: Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction.
abstract: OBJECTIVE
  A comparative assessment of (i) urinary continence status, (ii) quality of life, and (iii) sexuality in spinal cord injury patients prior to, and during intermittent catheterization with adjunctive intravesical oxybutynin therapy (Cystin: manufactured by Leiras Oy. Helsinki, Finland).
  
  
  METHODS
  A hospital, and community-based study of selected adult, male, spinal cord injury patients registered with the Regional Spinal Injuries Centre, Southport.
  
  
  METHODS
  Seven patients (mean age: 44.3 years) suffering from neuropathic bladder due to suprasacral spinal cord lesion of traumatic aetiology, and well settled in the community in the north-west of England were the subjects of this study. Before commencing the intermittent catheterization regime, these patients were on penile sheath drainage.
  
  
  METHODS
  Intermittent urethral catheterization was performed with sterile, single-use Nelaton catheters 5-6 times a day with intravesical instillation of oxybutynin 5 mg in 30 ml. 1-3 times a day for periods ranging from 14 to 30 months.
  
  
  METHODS
  Assessment of urinary continence, sexuality, and quality of life was made (i) at the outset before any intervention, (ii) during intermittent catheterization regime, and (iii) when the patients were using the oxybutynin bladder instillation along with intermittent catheterization.
  
  
  RESULTS
  Initially all the seven patients were constantly wearing penile sheaths and leg bags. When these patients performed intermittent catheterization 5-6 times in 24 h, they attempted to discard the penile sheath during the day but they were experiencing mild to moderate urine leak between catheterization. They were compelled to wear penile sheaths during night. Subsequently, five patients took oxybutynin by mouth, but developed an unacceptable degree of side-effects necessitating discontinuation of the medication. Following commencement of intravesical oxybutynin therapy, all of them were able to discard the penile sheaths and leg bags during the day as well as during the night. However, on waking-up after a full night's sleep, three patients found dampness of their undergarments 1-2 times per week. None of the patients experienced side-effects attributable either to the intermittent catheterization procedure, or to the intravesical oxybutynin therapy. The number of episodes of urinary infection requiring antibiotic therapy was 0.08/patient/month. All the seven patients noticed a remarkable improvement in the quality of life because they had achieved a high degree of continence. All the seven patients commented on the improved sense of their own sexuality which was attributed to (i) absence of incontinence episodes, (ii) improved self-image, and (iii) not wearing penile sheaths and leg bags.
  
  
  CONCLUSIONS
  These seven spinal cord injury patients achieved socially acceptable continence with improved quality of life, and enhanced sexuality with the intermittent urethral catheterization regime and intravesical oxybutynin therapy.
authors.affiliation: Regional Spinal Injuries Centre, District General Hospital, Southport, Merseyside, UK.
authors.forename: S
authors.initials: S
authors.lastname: Vaidyananthan
authors.forename: B M
authors.initials: BM
authors.lastname: Soni
authors.forename: E
authors.initials: E
authors.lastname: Brown
authors.forename: P
authors.initials: P
authors.lastname: Sett
authors.forename: K R
authors.initials: KR
authors.lastname: Krishnan
authors.forename: J
authors.initials: J
authors.lastname: Bingley
authors.forename: S
authors.initials: S
authors.lastname: Markey
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D019529:Sexuality / Q000502:physiology; D013119:Spinal Cord Injuries / Q000150:complications / Q000523:psychology* / Q000628:therapy*; D001743:Urinary Bladder; D001750:Urinary Bladder, Neurogenic / Q000209:etiology / Q000523:psychology* / Q000628:therapy*; D014546:Urinary Catheterization; D014549:Urinary Incontinence / Q000188:drug therapy / Q000523:psychology* / Q000628:therapy*
chemical_list: D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin